ImmunoGen - IMGN Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMGN shares.
View IMGN analyst ratings or view top-rated stocks.

4 analysts have issued 12-month target prices for ImmunoGen's shares. Their IMGN share price forecasts range from $9.00 to $22.00. On average, they predict the company's stock price to reach $13.33 in the next year. This suggests a possible upside of 250.0% from the stock's current price.
View analysts price targets for IMGN or view top-rated stocks among Wall Street analysts.

ImmunoGen's stock was trading at $4.96 at the start of the year. Since then, IMGN shares have decreased by 23.2% and is now trading at $3.81.
View the best growth stocks for 2023 here.

ImmunoGen saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 25,000,000 shares, an increase of 9.6% from the February 28th total of 22,800,000 shares. Based on an average daily trading volume, of 3,470,000 shares, the days-to-cover ratio is presently 7.2 days.
View ImmunoGen's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Friday, May 5th 2023.
View our IMGN earnings forecast.

ImmunoGen, Inc. (NASDAQ:IMGN) issued its earnings results on Wednesday, March, 1st. The biotechnology company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.06. The biotechnology company had revenue of $41.17 million for the quarter, compared to analyst estimates of $17.18 million. ImmunoGen had a negative trailing twelve-month return on equity of 100.18% and a negative net margin of 204.93%. The firm's revenue for the quarter was up 47.1% on a year-over-year basis. During the same period in the prior year, the business earned ($0.17) earnings per share.

ETFs with the largest weight of ImmunoGen (NASDAQ:IMGN) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), ALPS Medical Breakthroughs ETF (SBIO), Invesco Nasdaq Future Gen 200 ETF (QQQS), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC) and Invesco Nasdaq Biotechnology ETF (IBBQ).

ImmunoGen updated its FY 2023 earnings guidance on Wednesday, March, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $30.00 million-$35.00 million, compared to the consensus revenue estimate of $117.67 million.

16 employees have rated ImmunoGen Chief Executive Officer Mark J. Enyedy on Glassdoor.com. Mark J. Enyedy has an approval rating of 64% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Immunomedics (IMMU), Advanced Micro Devices (AMD), AbbVie (ABBV), Gilead Sciences (GILD), OPKO Health (OPK), AT&T (T) and Dynavax Technologies (DVAX).

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

ImmunoGen's stock is owned by many different retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (9.90%), Jennison Associates LLC (4.14%), Maverick Capital Ltd. (3.12%), Morgan Stanley (1.93%), Geode Capital Management LLC (1.74%) and Braidwell LP (1.57%).
View institutional ownership trends.

Shares of IMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IMGN stock can currently be purchased for approximately $3.81.

ImmunoGen (NASDAQ:IMGN) has a market capitalization of $861.24 million and generates $108.78 million in revenue each year. The biotechnology company earns $-222,930,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis.

The company employs 106 workers across the globe.

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The official website for the company is www.immunogen.com. The biotechnology company can be reached via phone at (781) 895-0600, via email at courtney.okonek@immunogen.com, or via fax at 781-895-0611.